
J.B. Chemicals (JBCHEPHARM) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
10.9B
Gross Profit
7.5B
68.27%
Operating Income
2.6B
23.60%
Net Income
2.0B
18.50%
EPS (Diluted)
₹12.75
Balance Sheet Metrics
Total Assets
42.7B
Total Liabilities
8.4B
Shareholders Equity
34.3B
Debt to Equity
0.24
Cash Flow Metrics
Revenue & Profitability Trend
J.B. Chemicals Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 38.6B | 34.5B | 31.2B | 24.2B | 20.2B |
Cost of Goods Sold | 13.4B | 12.0B | 11.8B | 8.4B | 7.2B |
Gross Profit | 25.2B | 22.4B | 19.3B | 15.8B | 13.0B |
Gross Margin % | 65.3% | 65.1% | 62.0% | 65.2% | 64.5% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 4.7B | 4.2B | 3.8B | 3.2B | 2.0B |
Other Operating Expenses | 3.4B | 3.3B | 3.0B | 6.0B | 2.0B |
Total Operating Expenses | 8.1B | 7.4B | 6.8B | 9.1B | 4.0B |
Operating Income | 8.5B | 7.5B | 5.9B | 4.7B | 4.9B |
Operating Margin % | 22.1% | 21.8% | 18.9% | 19.4% | 24.2% |
Non-Operating Items | |||||
Interest Income | 53.3M | 44.3M | 25.4M | 9.3M | 17.7M |
Interest Expense | 106.9M | 436.5M | 354.1M | 51.2M | 69.4M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 8.9B | 7.5B | 5.6B | 5.0B | 6.0B |
Income Tax | 2.3B | 2.0B | 1.5B | 1.2B | 1.5B |
Effective Tax Rate % | 25.7% | 26.5% | 26.2% | 23.5% | 24.9% |
Net Income | 6.6B | 5.5B | 4.1B | 3.9B | 4.5B |
Net Margin % | 17.1% | 16.0% | 13.2% | 15.9% | 22.2% |
Key Metrics | |||||
EBITDA | 10.4B | 9.0B | 7.0B | 5.8B | 5.7B |
EPS (Basic) | ₹42.45 | ₹35.66 | ₹26.50 | ₹24.93 | ₹28.98 |
EPS (Diluted) | ₹41.56 | ₹34.85 | ₹26.17 | ₹24.91 | ₹28.98 |
Basic Shares Outstanding | 155364761 | 154951521 | 77324995 | 154576815 | 154564194 |
Diluted Shares Outstanding | 155364761 | 154951521 | 77324995 | 154576815 | 154564194 |
Income Statement Trend
J.B. Chemicals Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 1.2B | 882.2M | 769.3M | 565.4M | 286.9M |
Short-term Investments | 3.4B | 3.7B | 1.9B | 1.1M | 6.6B |
Accounts Receivable | 8.2B | 6.9B | 5.8B | 5.6B | 3.9B |
Inventory | 5.3B | 5.0B | 4.3B | 4.1B | 3.5B |
Other Current Assets | 1.2B | 1.9B | 27.0K | 1.8B | 928.2M |
Total Current Assets | 19.2B | 18.5B | 15.3B | 12.7B | 15.5B |
Non-Current Assets | |||||
Property, Plant & Equipment | 980.4M | 886.2M | 837.6M | 814.3M | 794.6M |
Goodwill | 14.3B | 15.0B | 14.4B | 7.9B | 1.5B |
Intangible Assets | 13.2B | 13.9B | 13.2B | 6.7B | 321.1M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 155.2M | 3.0K | 33.7M | -90.3M | -73.2M |
Total Non-Current Assets | 23.5B | 21.4B | 20.3B | 13.3B | 6.9B |
Total Assets | 42.7B | 39.9B | 35.5B | 26.1B | 22.4B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 4.1B | 3.6B | 2.4B | 2.2B | 1.9B |
Short-term Debt | 215.4M | 3.4B | 1.7B | 339.4M | 398.5M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 222.8M | 242.0M | 236.5M | 88.2M | 99.4M |
Total Current Liabilities | 6.3B | 8.7B | 5.5B | 3.8B | 3.5B |
Non-Current Liabilities | |||||
Long-term Debt | 63.5M | 332.8M | 4.0B | 206.2M | 51.4M |
Deferred Tax Liabilities | 1.8B | 1.5B | 1.0B | 475.6M | 567.7M |
Other Non-Current Liabilities | 19.0M | 17.0M | 25.0M | 31.7M | 49.3M |
Total Non-Current Liabilities | 2.1B | 2.0B | 5.2B | 850.7M | 794.1M |
Total Liabilities | 8.4B | 10.7B | 10.7B | 4.7B | 4.2B |
Equity | |||||
Common Stock | 155.7M | 155.2M | 154.8M | 154.6M | 154.6M |
Retained Earnings | 29.4B | 25.2B | 21.3B | 18.4B | 15.8B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 34.3B | 29.2B | 24.8B | 21.4B | 18.1B |
Key Metrics | |||||
Total Debt | 278.9M | 3.8B | 5.7B | 545.6M | 449.9M |
Working Capital | 12.9B | 9.9B | 9.7B | 8.9B | 12.1B |
Balance Sheet Composition
J.B. Chemicals Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 8.9B | 7.5B | 5.6B | 5.0B | 6.0B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 549.0M | 419.7M | 693.7M | 626.5M | 0 |
Working Capital Changes | -762.4M | -1.4B | -622.7M | -3.6B | -1.4B |
Operating Cash Flow | 8.7B | 6.9B | 5.9B | 2.1B | 4.6B |
Investing Activities | |||||
Capital Expenditures | -964.7M | -1.3B | -717.3M | -550.9M | -209.5M |
Acquisitions | - | - | - | 0 | -85.0M |
Investment Purchases | -12.4B | -8.7B | -7.6B | -5.1B | -5.4B |
Investment Sales | 10.6B | 7.2B | 5.6B | 12.1B | 3.2B |
Investing Cash Flow | -2.8B | -2.7B | -2.7B | 6.5B | -2.5B |
Financing Activities | |||||
Share Repurchases | - | - | - | - | 0 |
Dividends Paid | -2.4B | -1.6B | -1.3B | -1.3B | -732.4M |
Debt Issuance | - | 0 | 6.1B | 0 | - |
Debt Repayment | 0 | -1.8B | -872.5M | 0 | - |
Financing Cash Flow | -5.6B | -3.3B | 4.0B | -1.3B | -729.2M |
Free Cash Flow | 7.8B | 5.4B | -1.4B | -5.4B | 2.7B |
Net Change in Cash | 365.2M | 865.5M | 7.2B | 7.3B | 1.3B |
Cash Flow Trend
J.B. Chemicals Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
39.84
Forward P/E
28.34
Price to Book
7.78
Price to Sales
6.70
PEG Ratio
2.84
Profitability Ratios
Profit Margin
17.10%
Operating Margin
23.60%
Return on Equity
19.21%
Return on Assets
15.43%
Financial Health
Current Ratio
3.04
Debt to Equity
0.81
Beta
-0.11
Per Share Data
EPS (TTM)
₹43.09
Book Value per Share
₹220.54
Revenue per Share
₹257.72
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
jbchepharm | 268.6B | 39.84 | 7.78 | 19.21% | 17.10% | 0.81 |
Sun Pharmaceutical | 3.9T | 37.88 | 5.45 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 70.42 | 10.88 | 14.64% | 23.89% | 0.03 |
Cipla | 1.3T | 23.42 | 4.05 | 16.85% | 19.62% | 1.40 |
Torrent | 1.2T | 61.35 | 16.15 | 25.18% | 16.92% | 42.81 |
Dr. Reddy's | 1.0T | 18.52 | 3.00 | 17.71% | 16.99% | 13.75 |
Financial data is updated regularly. All figures are in the company's reporting currency.